1. Home
  2. KOS vs LBRX Comparison

KOS vs LBRX Comparison

Compare KOS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$0.94

Market Cap

475.3M

Sector

Energy

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$22.10

Market Cap

533.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOS
LBRX
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
475.3M
533.1M
IPO Year
2011
2025

Fundamental Metrics

Financial Performance
Metric
KOS
LBRX
Price
$0.94
$22.10
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$2.72
$49.00
AVG Volume (30 Days)
17.6M
463.7K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,392,234,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$13.36
52 Week High
$4.01
$23.15

Technical Indicators

Market Signals
Indicator
KOS
LBRX
Relative Strength Index (RSI) 32.66 N/A
Support Level $0.87 N/A
Resistance Level $1.06 N/A
Average True Range (ATR) 0.09 0.00
MACD 0.01 0.00
Stochastic Oscillator 21.98 0.00

Price Performance

Historical Comparison
KOS
LBRX

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: